Quantcast

Latest cardiomyopathy Stories

2014-09-17 08:30:11

- Up to $200 Million Collaboration to Support Pioneering Science and New Treatments - PARIS and SOUTH SAN FRANCISCO, Calif., Sept. 17, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) and MyoKardia, Inc., a privately-held company leading the development of precision therapies for genetic heart disease, announced today a worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most...

2014-08-23 23:01:03

MarketOptimizer.org adds “Cardiomyopathy Global Clinical Trials Review, H2, 2014” to its store. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. Dallas, Texas (PRWEB) August 23, 2014 Cardiomyopathy (heart muscle disease) is the measurable deterioration of the function of the myocardium (the heart muscle) for any reason, usually leading to heart failure; common symptoms are dyspnea (breathlessness) and...

2014-07-23 23:26:50

EECP Treatment is FDA-Cleared for Refractory Angina and Offered at Dr. Weaver’s EECP Independent Outpatient Facility in the U.S. Los Angeles, CA (PRWEB) July 22, 2014 Ronald S. Weaver, MD, owner of Global Cardio Care Centers in Inglewood, Calif., today announced a heart transplant patient with cardiomyopathy has successfully completed a course of Enhanced External Counterpulsation (EECP) therapy at Global Cardio Care Centers and is no longer a candidate for heart transplant. The...

2014-05-21 23:01:11

International Experts to Educate About Hypertrophic Cardiomyopathy in Morristown, NJ Morristown, NJ (PRWEB) May 21, 2014 On May 30-June 1, the Hypertrophic Cardiomyopathy Association (HCMA) will hold its 16th annual meeting, “Navigating the HCM Heart” at Morristown Medical Center. According to HCMA, a national, nonprofit organization (4hcm.org), HCM is the most common of all genetic heart conditions, affecting 1 in 500 people – or as many as an estimated 600,000 people in the United...

2014-05-12 23:00:11

Humility of Mary Health Partners is among the first healthcare providers in the country to implant the world’s first commercially available subcutaneous implantable defibrillator. Youngstown, Ohio (PRWEB) May 13, 2014 Humility of Mary Health Partners is among the first healthcare providers in the country to implant a revolutionary new cardiac defibrillator under the skin of patients at risk for sudden cardiac arrest. The new device, called an S-ICD, was developed by Cameron...

2014-05-12 08:32:54

Newly published findings by nationally recognized pediatric cardiologist Dr. Steven Lipshultz provide "very hopeful" evidence that survivors of often fatal ailment can regain "normal size and function" of disease-damaged areas of heart. DETROIT, May 12, 2014 /PRNewswire-USNewswire/ -- After two decades of arduous research, a National Institutes of Health (NIH)-funded investigator at the Children's Hospital of Michigan (CHM) at the Detroit Medical Center (DMC) and the Wayne State...

2014-04-28 23:04:36

Findings Show Several FDA-Approved Drugs May also be Effective in Patients Diagnosed with Dilated Cardiomyopathy New York, NY (PRWEB) April 28, 2014 Scientists at Icahn School of Medicine at Mount Sinai, along with collaborators at institutions in India, Italy, and Japan, have identified the first gene linked to childhood-onset familial dilated cardiomyopathy (DCM), one of the most common heart muscle diseases in children. It is a progressive and potentially fatal heart condition...

2014-04-17 00:21:10

DUBLIN, April 17, 2014 /PRNewswire/ -- Heart Metabolics Limited, a new Irish biotechnology company focused on development of drugs for cardio-metabolic diseases, has announced the completion of a $20 million Series A financing from venBio, Seroba Kernel Life Sciences, Brandon Capital Partners (on behalf of AustralianSuper) and AshHill. The proceeds from this financing have supported Heart Metabolics Limited in acquiring a Phase 3-ready drug candidate and related preclinical drug...

2014-04-06 16:20:26

AAVLife aimed at advancing gene therapy for cardiomyopathy in Friedreich's ataxia to clinic DOWNINGTOWN, Pa., April 6, 2014 /PRNewswire-USNewswire/ -- The Friedreich's Ataxia Research Alliance (FARA) is pleased to recognize the ground-breaking gene-therapy research of FARA-funded scientist Dr. Hélène Puccio. In the current online issue of Nature Medicine, Dr. Puccio and her colleagues present significant results demonstrating that gene-replacement therapy using an adeno-associated...

2014-02-14 16:24:52

CARLSBAD, Calif., Feb. 14, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending ISIS-TTR(Rx) for designation as an orphan medicinal product for the treatment of ATTR-Amyloidosis to the European Commission (EC). The opinion will be subject to review by the EC, which ultimately grants the decision on orphan drug designation. ATTR-Amyloidosis, or TTR amyloidosis,...


Latest cardiomyopathy Reference Libraries

0_f2af62ab4a621762b08a981d4f8d6266
2008-05-22 18:26:48

The English Cocker Spaniel is a hunting dog, used to drive game toward the guns. This breed has been around for over 500 years. During the mid 1800s, several types of dogs were classified as Cockers; however the breeds were reclassified later in the late 1800s once breed standards were developed. There are two types of Cocker Spaniel, the American and the English. These were shown together until 1936, when the English Cocker received status as a separate breed. The two somewhat resemble each...

More Articles (1 articles) »
Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.